Ginkgo Bioworks expands gene therapy capabilities through strategic acquisitions and partnerships.

Ginkgo Bioworks has acquired StrideBio's adeno-associated virus (AAV) capsid assets, which are in the discovery or preclinical stage and focused on cardiovascular diseases. Sanofi has broken ground on a new formulation and filling facility at its site in Swiftwater, PA, which will be a two-story building that will fill both syringes and vials. Amgen's Prolia/Xgeva (denosumab) has shown promise in a small NIH-funded Phase II study for a rare bone disease. The FDA has released its fourth (of four) patient-focused drug development guidance documents, with this latest draft featuring advice on how to collect and submit data on the individual experiences of patients to inform regulatory decisions. PureTech has expressed interest in buying back its weight loss pill spinout Gelesis after a lackluster SPAC.